Biohaven Pharmaceutical Holding Co Ltd (BHVN) — Strategic Asset Allocation Index
Biohaven Pharmaceutical Holding Co Ltd (BHVN) has a Strategic Asset Allocation Index of 17.2% as of September 2023. Strategic assets (PP&E of $49.89 Million plus long-term investments of $-) total $49.89 Million, measured against net assets of $290.01 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check BHVN asset resilience ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Biohaven Pharmaceutical Holding Co Ltd Strategic Asset Allocation Index (2020–2022)
This chart shows how Biohaven Pharmaceutical Holding Co Ltd's Strategic Asset Allocation Index has evolved across 3 annual periods from 2020 to 2022. As of September 2023, the index stands at 17.2%, representing strategic assets of $49.89 Million against net assets of $290.01 Million USD. See Biohaven Pharmaceutical Holding Co Ltd free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Biohaven Pharmaceutical Holding Co Ltd (2020–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Biohaven Pharmaceutical Holding Co Ltd from 2020 to 2022, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see BHVN market cap overview.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 9.7% | $52.14 Million | $52.14 Million | $0.00 | $538.77 Million | ▼ -12.2 pp |
| 2021 | 21.9% | $20.69 Million | $14.69 Million | $6.00 Million | $94.69 Million | ▼ -5.2 pp |
| 2020 | 27.0% | $20.74 Million | $13.56 Million | $7.18 Million | $76.78 Million | — |